NCT07175922Recruiting
Research Into the Expression of the csgA-gene and How it Changes in Patients With Parkinson's Disease
Evaluation of csgA Prevalence, Gene Expression and Week-to-Week Variability in Participants With Parkinson's Disease and a History of Gastrointestinal Dysfunction
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
This study seeks to understand the prevalence and variability of a gut bacteria gene called csgA in people with Parkinson's Disease. This understanding could inform development of potential new therapies targeting the gut in Parkinson's Disease.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 22 Jul 2025
- Start date
- 25 Sept 2025
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Vertero Therapeutics
- Diseases
- Parkinson disease
- NCT number
- NCT07175922
What you commit to
- Study type: Observational
- Planned participants: 200
- From 25 Sept 2025 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Major GI surgery (excluding appendectomy/cholecystectomy), such as bariatric surgery, gastrectomy, esophagectomy, vagotomy, small intestine surgeries, any type of colectomy, colostomy and anorectal surgeries if deemed clinically significant by the investigator
- Use of systemic antibiotics within 30 days prior to enrollment
Other illness
- Any known GI disorder if deemed clinically significant by the investigator. GI disorders may include, but are not limited to: Crohn's disease, ulcerative colitis, celiac disease, irritable bowel syndrome, or lactose intolerance
- Recent GI infection in the past 3 months if deemed clinically significant by the investigator.
- Any known current or past eating disorder if deemed clinically significant by the investigator
Who the study is looking for
- Between 18-80 years of age at ICF signing (inclusive)
- A diagnosis of PD within 10 years from the time of ICF signing
- Current or history of gastrointestinal (GI) dysfunction or constipation based on screening assessment
- All participants must understand and provide written informed consent prior to any study specific procedures
- Able to speak, read, and understand study procedures in Dutch sufficiently to allow completion of all study assessments
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Human Drug Research Coordinator of this site? Confirm its status | Leiden | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.